You just read:

Auven Therapeutics and BELLUS Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA™, an Experimental Drug in Phase III Development for the Treatment Of AA Amyloidosis

News provided by

BELLUS Health Inc.

May 07, 2014, 08:00 ET